BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 326,932 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 326,932 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now owns 5,371,515 shares of the company’s stock, valued at $194,932,279.35. This represents a 5.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Neil Kumar also recently made the following trade(s):

• On Tuesday, November 19th, Neil Kumar sold 27,389 shares of BridgeBio Pharma stock. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49.

BridgeBio Pharma Price Performance

BBIO stock opened at $34.21 on Friday. The company has a fifty day moving average price of $29.89 and a 200 day moving average price of $27.16. BridgeBio Pharma, Inc. has a 12 month low of $21.62 and a 12 month high of $41.04. The company has a market cap of $6.47 billion, a price-to-earnings ratio of -14.19 and a beta of 1.05.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research note on Monday, December 16th. Leerink Partners reduced their price objective on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Bank of America boosted their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Evercore ISI boosted their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Finally, Scotiabank boosted their price objective on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus target price of $49.00.

Hedge Funds Weigh In On BridgeBio Pharma

Several institutional investors have recently bought and sold shares of the company. State of New Jersey Common Pension Fund D increased its stake in BridgeBio Pharma by 21.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 93,131 shares of the company’s stock valued at $2,556,000 after buying an additional 16,545 shares during the period. Rhumbline Advisers increased its stake in BridgeBio Pharma by 2.3% in the 4th quarter. Rhumbline Advisers now owns 219,120 shares of the company’s stock valued at $6,013,000 after buying an additional 5,007 shares during the period. Legato Capital Management LLC acquired a new position in BridgeBio Pharma in the 4th quarter valued at $210,000. Harvey Capital Management Inc. acquired a new position in BridgeBio Pharma in the 4th quarter valued at $354,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in BridgeBio Pharma by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 40,073 shares of the company’s stock valued at $1,100,000 after buying an additional 3,908 shares during the period. 99.85% of the stock is owned by institutional investors and hedge funds.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.